Peptides As Therapeutics with Enhanced Bioactivity
The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Abstract
The development of techniques for efficient peptide production renewed interest in peptides as therapeutics. Numerous modifications for improving stability, transport and affinity profiles now exist. Several new adjuvant and carrier systems have also been developed, enhancing the immunogenicity of peptides thus allowing their development as vaccines. This review describes the established and experimental approaches for manufacturing peptide drugs and highlights the techniques currently used for improving their drug like properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
Merrifield, R. B. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00897a025 · Cited by 7,647 · cited 14×
“Two chemical methodologiessolution-phase (SPS), and solid-phase peptide synthesis (SPPS) [4] - are the predominant methods of chemical synthesis, but many other approaches, including hybrid synthesis and chemoselective ligation, have also been studied.”
MethodInfluentialSynthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476 · cited 1×
“Other approaches included the use of other unnatural residues, modification of peptide bonds, termini protection/modifications and conjugation to carrier constructs, such as biocompatible polymers [72].”
BackgroundActivation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349 · cited 2×
“enhanced stability over the unmodified BID BH3 peptide in mouse serum [142].”
BackgroundZuckermann, R. N., Kerr, J. M., Kent, S. B. H., & Moos, W. H. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00052a076 · Cited by 1,277 · cited 1×
“Zuckermann and colleagues introduced a family of peptidomimetics called ‘peptoids’ [114].”
BackgroundTam, J. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5409 · Cited by 1,251 · cited 2×
“Unlike some other formulations, peptide-based subunit vaccines exist as one entity inclusive of all components essential for a successful vaccine, incorporating adjuvant, carrier and antigen [46, 47].”
BackgroundFood-derived peptides with biological activity: from research to food applications.
Hartmann, R., & Meisel, H. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.01.013 · Cited by 1,102 · cited 1×
“Peptides were derived from bovine milk proteins that had angiotensin converting enzyme inhibitory, immunomodulatory, antithrombotic and hypocholesterolemic activities [36-38].”
MethodContemporary strategies for peptide macrocyclization
White, C. J., & Yudin, A. K. (2011) · Nature Chemistry · doi:10.1038/nchem.1062 · Cited by 1,088 · cited 1×
“Since the 1940s, the interest in cyclic peptides has grown substantially [134].”
BackgroundSCHNölzer, M., ALEWOOD, P., JONES, A., ALEWOOD, D., & KENT, S. B. H. (1992) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1992.tb00291.x · Cited by 1,049
Seebach, D., Overhand, M., Kühnle, F. N. M., Martinoni, B., Oberer, L., Hommel, U., & Widmer, H. (1996) · Helvetica Chimica Acta · doi:10.1002/hlca.19960790402 · Cited by 734 · cited 1×
“-Peptidomimetics also assumed defined helical structures, with as few as six residues able to form a helix [121].”
BackgroundKnudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700 · cited 2×
“2 to 13 hours after subcutaneous administration [41].”
BackgroundEncoding multiple unnatural amino acids via evolution of a quadruplet-decoding ribosome
Neumann, H., Wang, K., Davis, L., Garcia-Alai, M., & Chin, J. W. (2010) · Nature · doi:10.1038/nature08817 · Cited by 622 · cited 1×
“incorporated alkyne- and azidecontaining amino acids to facilitate a rapid cycloaddition, to form a triazole cross-linkage for enhanced proteolytic and structural stability [35].”
BackgroundLarge-scale manufacture of peptide therapeutics by chemical synthesis
Bray, B. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1133 · Cited by 598 · cited 16×
“Two chemical methodologiessolution-phase (SPS), and solid-phase peptide synthesis (SPPS) [4] - are the predominant methods of chemical synthesis, but many other approaches, including hybrid synthesis and chemoselective ligation, have also been studied.”
BackgroundMethodInfluentialTHE SYNTHESIS OF AN OCTAPEPTIDE AMIDE WITH THE HORMONAL ACTIVITY OF OXYTOCIN
Vigneaud, V. D., Ressler, C., Swan, C. J. M., Roberts, C. W., Katsoyannis, P. G., & Gordon, S. (1953) · Journal of the American Chemical Society · doi:10.1021/ja01115a553 · Cited by 584 · cited 1×
“First described by du Vigneud in 1953, the SPS method was used for the production of most commercial peptide therapeutics [5].”
MethodReactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide
Bernal, F., Tyler, A. F., Korsmeyer, S. J., Walensky, L. D., & Verdine, G. L. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0693587 · Cited by 556
Oral Delivery of Peptide Drugs: Barriers and Developments
Hamman, J. H., Enslin, G. M., & Kotz??, A. F. (2005) · BioDrugs · doi:10.2165/00063030-200519030-00003 · Cited by 499
Murray, B., & FitzGerald, R. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780363068 · Cited by 485 · cited 1×
“Peptides were derived from bovine milk proteins that had angiotensin converting enzyme inhibitory, immunomodulatory, antithrombotic and hypocholesterolemic activities [36-38].”
MethodCombinatorial alanine-scanning
Morrison, K. L., & Weiss, G. A. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00206-4 · Cited by 443
Miller, S. M., Simon, R. J., Ng, S., Zuckermann, R. N., Kerr, J. M., & Moos, W. H. (1995) · Drug Development Research · doi:10.1002/ddr.430350105 · Cited by 429 · cited 1×
“The difference between peptides and peptoids was that the amino acid side chain shifted to the -amino group [115].”
BackgroundHydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
Bird, G. H., Madani, N., Perry, A. F., Princiotto, A. M., Supko, J. G., He, X., Gavathiotis, E., Sodroski, J. G., & Walensky, L. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002713107 · Cited by 347 · cited 1×
“It was suggested that these staples create a “proteolytic shield” by reinforcing an -helix and blocking proteolysis at the staple sites completely [145].”
BackgroundPseudo-Prolines as a Solubilizing, Structure-Disrupting Protection Technique in Peptide Synthesis
Wöhr, T., Wahl, F., Nefzi, A., Rohwedder, B., Sato, T., Sun, X., & Mutter, M. (1996) · Journal of the American Chemical Society · doi:10.1021/ja961509q · Cited by 345 · cited 1×
“Pseudo-proline ( Pro) modified amino acid residues were designed to minimize aggregation and racemization when synthesizing difficult peptide sequences [18].”
BackgroundDesigning peptide receptor agonists and antagonists
Hruby, V. J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd939 · Cited by 344 · cited 1×
“Scanning was usually performed using alanine (Ala-scan) [150] and D-amino acids (D-scan) [151].”
MethodSerum Stabilities of Short Tryptophan- and Arginine-Rich Antimicrobial Peptide Analogs
Nguyen, L. T., Chau, J. K., Perry, N. A., de Boer, L., Zaat, S. A. J., & Vogel, H. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012684 · Cited by 333 · cited 1×
“Examples of modifications were the use of N-pyroglutamate, C-amidation, acetylation [74], pegylation (PEG) [75] and conjugation of carbohydrate moieties [76-78].”
BackgroundKumagai, A. K., Eisenberg, J. B., & Pardridge, W. M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48160-4 · Cited by 325 · cited 5×
“For example, desmorphin coupled to the OX26 carrier or -endorphin coupled to cationized albumin for delivery across the BBB [129, 130].”
BackgroundInfluentialTherapeutic application of peptides and proteins: parenteral forever?
Antosova, Z., Mackova, M., Kral, V., & Macek, T. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.07.009 · Cited by 324 · cited 1×
“Syntocinon®, Novartis), has been approved for intranasal delivery [90, 91].”
BackgroundEnzymatic barriers for GI peptide and protein delivery.
Woodley, J. F. (1994) · PubMed · Cited by 291
ChemMatrix, a Poly(ethylene glycol)-Based Support for the Solid-Phase Synthesis of Complex Peptides
García-Martín, F., Quintanar-Audelo, M., García-Ramos, Y., Cruz, L. J., Gravel, C., Furic, R., Côté, S., Tulla-Puche, J., & Albericio, F. (2006) · Journal of Combinatorial Chemistry · doi:10.1021/cc0600019 · Cited by 285 · cited 2×
“The use of polyethylene glycol (PEG)-based resins, particularly ChemMatrix® (CM), showed benefits over traditional polystyrene-based resins [20, 21].”
MethodExtending Synthetic Access to Proteins with a Removable Acyl Transfer Auxiliary
Offer, J., Boddy, C. N. C., & Dawson, P. E. (2002) · Journal of the American Chemical Society · doi:10.1021/ja016731w · Cited by 276 · cited 1×
“A modified method used auxillary thiols in place of the cysteine residues, which were removed at the site of ligation and allowed the formation of a noncysteine linkage [14, 15].”
MethodGarcía-Echeverría, C., Chène, P., Blommers, M. J. J., & Furet, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990966p · Cited by 246 · cited 1×
“A more complicated modification of a tumor-suppressing p53-derived peptide, including the substitution of unnatural amino acids, led to a more stabilized helix, with an increase of affinity to the Hdm2 oncoprotein up to 63-fold [112].”
BackgroundMerkler, D. J. (1994) · Enzyme and Microbial Technology · doi:10.1016/0141-0229(94)90014-0 · Cited by 232 · cited 1×
“glycosylation [39], amidation [40]).”
Immunoregulatory peptides in bovine milk
Gill, H. S., Doull, F., Rutherfurd, K. J., & Cross, M. L. (2000) · British Journal of Nutrition · doi:10.1017/s0007114500002336 · Cited by 231 · cited 1×
“Peptides were derived from bovine milk proteins that had angiotensin converting enzyme inhibitory, immunomodulatory, antithrombotic and hypocholesterolemic activities [36-38].”
MethodPeptide synthesis: chemical or enzymatic
Guzman, F., Barberis, S., & Illanes, A. (2007) · Electronic Journal of Biotechnology · doi:10.2225/vol10-issue2-fulltext-13 · Cited by 220
Recent Advances in Protein and Peptide Drug Delivery Systems
Kumar Malik, D., Baboota, S., Ahuja, A., Hasan, S., & Ali, J. (2007) · Current Drug Delivery · doi:10.2174/156720107780362339 · Cited by 216
Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles
ZHANG, X. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.08.009 · Cited by 197 · cited 1×
“Intranasal delivery of insulin has been thoroughly investigated and a number of nanoparticle systems have recently shown promise in animal models [87, 88].”
BackgroundEnhanced coupling efficiency in solid-phase peptide synthesis by microwave irradiation
Yu, H. M., Chen, S. T., & Wang, K. T. (1992) · The Journal of Organic Chemistry · doi:10.1021/jo00044a001 · Cited by 181
Chen, X., Fernando, G. J. P., Crichton, M. L., Flaim, C., Yukiko, S. R., Fairmaid, E. J., Corbett, H. J., Primiero, C. A., Ansaldo, A. B., Frazer, I. H., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.026 · Cited by 180
Polyacrylate Dendrimer Nanoparticles: A Self‐Adjuvanting Vaccine Delivery System
Skwarczynski, M., Zaman, M., Urbani, C. N., Lin, I., Jia, Z., Batzloff, M. R., Good, M. F., Monteiro, M. J., & Toth, I. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201002221 · Cited by 177 · cited 1×
“High antibody titers were achieved following subcutaneous administration in mice [68].”
BackgroundZeng, W., Ghosh, S., Lau, Y. F., Brown, L. E., & Jackson, D. C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4905 · Cited by 176 · cited 1×
“The conjugation of bacterial lipid constructs, such as Pam3Cys, to synthetic peptides induced high antibody titers [50, 51].”
BackgroundPeptides and Proteins as a Continuing Exciting Source of Inspiration for Peptidomimetics
Liskamp, R. M. J., Rijkers, D. T. S., Kruijtzer, J. A. W., & Kemmink, J. (2011) · ChemBioChem · doi:10.1002/cbic.201000717 · Cited by 175 · cited 1×
“This group of peptide analogues was classified as ‘peptidomimetics’ [113].”
BackgroundAlyautdin, R. N., Gothier, D., Петров, Kharkevich, D. A., & Kreuter, J. (1995) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 169
Hydrophobic Vancomycin Derivatives with Improved ADME Properties: Discovery of Telavancin (TD-6424)
LEADBETTER, M. R., ADAMS, S. M., BAZZINI, B., FATHEREE, P. R., KARR, D. E., KRAUSE, K. M., LAM, B. M. T., LINSELL, M. S., NODWELL, M. B., PACE, J. L., et al. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.326 · Cited by 165 · cited 1×
“Used to overcome resistance and to improve ADME properties, televancin is made by the lipidation of vancomycin (a glycopeptide antibiotic synthesized using fermentation techniques) [43].”
BackgroundNon-pathogenic trypanosomatid protozoa as a platform for protein research and production
Breitling, R., Klingner, S., Callewaert, N., Pietrucha, R., Geyer, A., Ehrlich, G., Hartung, R., Müller, A., Contreras, R., Beverley, S. M., et al. (2002) · Protein Expression and Purification · doi:10.1016/s1046-5928(02)00001-3 · Cited by 162 · cited 1×
“Autonomous cells were used traditionally but a number of alternative organisms such as Leishmania tarentolae (a protozoan parasite of lizards) were developed [32] and have been shown to be cheaper than previous systems [33].”
BackgroundTaylor, M., Moore, S., Mayes, J., Parkin, E., Beeg, M., Canovi, M., Gobbi, M., Mann, D. M. A., & Allsop, D. (2010) · Biochemistry · doi:10.1021/bi100144m · Cited by 160 · cited 1×
“demonstrated that the RI analogue remained intact after 24 h, by which time the parent peptide has been completely degraded [110].”
BackgroundBrain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats
Dufès, C., Olivier, J., Gaillard, F. P., Gaillard, A., Couet, W. R., & Jm, M. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00039-5 · Cited by 157 · cited 1×
“In one example, vasoactive intestinal peptide was shown to reach the brain when delivered intranasally, whereas intravenous delivery was unsuccessful, indicating a fraction passed through a direct transport pathway [89].”
BackgroundSelf-Adjuvanting Lipopeptide Vaccines
Moyle, P., & Toth, I. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783503249 · Cited by 155 · cited 3×
“This was due to the action of cell-surface receptors, such as the Toll-like receptors, which recognized structurally conserved pathogenassociated molecular patterns [45].”
BackgroundInfluentialClaudon, P., Violette, A., Lamour, K., Décossas, M., Fournel, S., Heurtault, B., Godet, J., Mély, Y., Jamart‐Grégoire, B., Averlant‐Petit, M., et al. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200905591 · Cited by 155 · cited 1×
“Urea peptidomimetics and their hybrids mimicked the helical structure of host-defense peptides for use as antimicrobials [120].”
BackgroundFerdinandi, E. S., Brazeau, P., High, K. A., Procter, B. G., Fennell, S., & Dubreuil, P. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00008.x · Cited by 153 · cited 1×
“Modification of tesamorelin with a hexenoyl moiety enhanced resistance to dipeptidyl peptidase 4, which deactivated the parent peptide: growth hormone-releasing hormone [97].”
BackgroundXu, D., Trajkovic, V., Hunter, D., Leung, B. P., Schulz, K., Gracie, J. A., McInnes, I. B., & Liew, F. Y. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200011)30:11<3147::aid-immu3147>3.0.co;2-j · Cited by 153
To protect peptide pharmaceuticals against peptidases
Rink, R., Arkema-Meter, A., Baudoin, I., Post, E., Kuipers, A., Nelemans, S. A., Akanbi, M. H. J., & Moll, G. N. (2010) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2010.02.010 · Cited by 153 · cited 5×
“the conotoxins), somatostatin, oxytocin [123], LHRH [136] and insulin with sulfide-based bridges were all shown to be potent peptides.”
BackgroundInfluentialSpecies-independent translational leaders facilitate cell-free expression
Mureev, S., Kovtun, O., Nguyen, U. T. T., & Alexandrov, K. A. (2009) · Nature Biotechnology · doi:10.1038/nbt.1556 · Cited by 151 · cited 1×
“Autonomous cells were used traditionally but a number of alternative organisms such as Leishmania tarentolae (a protozoan parasite of lizards) were developed [32] and have been shown to be cheaper than previous systems [33].”
BackgroundWiesmüller, K. H., Jung, G., & Hess, G. (1989) · Vaccine · doi:10.1016/0264-410x(89)90007-8 · Cited by 147 · cited 1×
“coli, tripalmitoyl-S-glyceryl cysteine or Pam3Cys, was elucidated in 1983 [49].”
BackgroundModulating Oxytocin Activity and Plasma Stability by Disulfide Bond Engineering
Muttenthaler, M., Andersson, A., de Araujo, A. D., Dekan, Z., Lewis, R. J., & Alewood, P. F. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100989w · Cited by 136 · cited 2×
“In this case, selenocystein technology (based on the replacement of sulfur with selenium) was used to produce more stable and potent nicotinic antagonists [123].”
BackgroundMethodPeptide-Based Subunit Nanovaccines
Skwarczynski, M., & Toth, I. (2011) · Current Drug Delivery · doi:10.2174/156720111795256192 · Cited by 129
Cell-penetrating TAT peptide in drug delivery systems: Proteolytic stability requirements
Koren, E., Apte, A., Sawant, R. R., Grunwald, J., & Torchilin, V. P. (2011) · Drug Delivery · doi:10.3109/10717544.2011.567310 · Cited by 125 · cited 1×
“A HIV cell-penetrating TAT peptide was shielded successfully using PEG chains attached to the surface of micelles [127].”
MethodZhou, N., Luo, Z., Luo, J., Fan, X., Cayabyab, M. J., Hiraoka, M., Liu, D., Han, X., Pesavento, J. J., Dong, C., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202063200 · Cited by 119 · cited 1×
“The natural L-peptide was degraded within 24 h, whereas the D-peptide showed no signs of degradation, even after 72 h [107].”
BackgroundProdrugs: bridging pharmacodynamic/pharmacokinetic gaps
Testa, B. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.620 · Cited by 117 · cited 1×
“The lipid was attached via either a stable linkage, or a labile one, creating a pro-drug [93, 94].”
BackgroundNasal Spray Desmopressin (DDAVP) for Mild Hemophilia A and von Willebrand Disease
Rose, E. H., & Aledort, L. M. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-7-563 · Cited by 115 · cited 1×
“Syntocinon®, Novartis), has been approved for intranasal delivery [90, 91].”
BackgroundThe solid phase synthesis of oligoureas
Kim, J., Bi, Y., Paikoff, S. J., & Schultz, P. G. (1996) · Tetrahedron Letters · doi:10.1016/0040-4039(96)01100-8 · Cited by 112 · cited 1×
“Most peptidomimetics were synthesized using altered SPPS protocols [117-119].”
MethodStymiest, J. L., Mitchell, B. F., Wong, S., & Vederas, J. C. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo050539l · Cited by 104 · cited 1×
“Enkephalin [137], oxytocin [138], -conotoxin IMI [139] and lanreotide [140] were subjected to RCM modifications.”
MethodEgleton, R. D., Mitchell, S. A., Huber, J. D., Palian, M. M., Polt, R. L., & Davis, T. P. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29218-1 · Cited by 102 · cited 2×
“Examples of modifications were the use of N-pyroglutamate, C-amidation, acetylation [74], pegylation (PEG) [75] and conjugation of carbohydrate moieties [76-78].”
BackgroundTargeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide
Hatakeyama, S., Sugihara, K., Shibata, T. K., Nakayama, J., Akama, T. O., Tamura, N., Wong, S.-M., Bobkov, A. A., Takano, Y., Οhyama, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105057108 · Cited by 98 · cited 1×
“Another peptide, IF7, targeted tumor vasculature within minutes, as demonstrated by conjugation to a florescent moiety and enhanced action after conjugation to the anticancer drug, SN-38 [132].”
BackgroundRousselle, C., Clair, P., Smirnova, M., Kolesnikov, Y. A., Pasternak, G. W., Gac-Breton, S., Rees, A. R., Scherrmann, J., & Temsamani, J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048520 · Cited by 90 · cited 1×
“These chimeric peptides provided enhanced antinociception in mice and passed through the BBB by adsorptive-mediated endocytosis [128].”
BackgroundReprogramming the Genetic Code: From Triplet to Quadruplet Codes
Wang, K., Schmied, W. H., & Chin, J. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201105016 · Cited by 88 · cited 1×
“Extended anticodon tRNAs (pre-aminoacylated with unnatural amino acids) substituted natural tRNAs to selectively include these amino acids in a number of sequences [34].”
BackgroundSelf-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine
Zaman, M., Skwarczyński, M., Malcolm, J., Urbani, C. N., Jia, Z., Batzloff, M. R., Good, M. F., Monteiro, M. J., & Tóth, I. (2010) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.10.002 · Cited by 87 · cited 1×
“These antibodies were able to opsonize Group A Streptococci [67].”
BackgroundMartemyanov, K. A., Shirokov, V. A., Kurnasov, O. V., Gudkov, A. T., & Spirin, A. S. (2001) · Protein Expression and Purification · doi:10.1006/prep.2001.1400 · Cited by 80 · cited 1×
“(3) [31].”
Adams, E. W., Ratner, D. M., Seeberger, P. H., & Hacohen, N. (2008) · ChemBioChem · doi:10.1002/cbic.200700310 · Cited by 80 · cited 2×
“The conjugation of carbohydrate moieties to ovalbumin (OVA, derived from egg white protein) enhanced antigen presentation [64], while coating liposome-protamine-DNA nanoparticles with mannan enhanced the immunogenicity of a human papilloma virus-derived peptide epitope [65].”
BackgroundMethodZhong, G., Toth, I., Reid, R., & Brunham, R. C. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.7.3728 · Cited by 77 · cited 2×
“trachomatis) [56], human papillomavirus [57], and Streptococcus pyogenes [58-62].”
BackgroundNovel approaches to enhance pulmonary delivery of proteins and peptides.
Scheuch, G., & Siekmeier, R. (2007) · PubMed · Cited by 76
Stability of peptides and therapeutic success in cancer
Pernot, M., Vanderesse, R., Frochot, C., Guillemin, F. H., & Barberi‐Heyob, M. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.574126 · Cited by 76 · cited 1×
“However, peptides with strong overall positive charges interact with the phosphate heads of lipids, thus are better able to cross biological membranes [73].”
BackgroundCyclization of conotoxins to improve their biopharmaceutical properties
Clark, R. J., Akcan, M., Kaas, Q., Daly, N. L., & Craik, D. J. (2010) · Toxicon · doi:10.1016/j.toxicon.2010.12.003 · Cited by 74 · cited 1×
“Backbone cyclization of natural conotoxin was shown to be effective for the development of an orally active peptide for the treatment of neuropathic pain [141].”
BackgroundAndrieu, M., Loing, E., Desoutter, J.-F., Connan, F., Choppin, J., Gras‐Masse, H., Hanau, D., Dautry‐Varsat, A., Guillet, J., & Hosmalin, A. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200011)30:11<3256::aid-immu3256>3.0.co;2-h · Cited by 72 · cited 1×
“though it was suggested that they assisted in the anchoring, internalization and presentation of the attached antigens [52].”
BackgroundMicrowave‐assisted RCM for the synthesis of carbocyclic peptides
Robinson, A. J., Elaridi, J., van Lierop, B. J., Mujcinovic, S., & Jackson, W. R. (2007) · Journal of Peptide Science · doi:10.1002/psc.840 · Cited by 70 · cited 1×
“Enkephalin [137], oxytocin [138], -conotoxin IMI [139] and lanreotide [140] were subjected to RCM modifications.”
MethodNomoto, M., Yamada, K., Haga, M., & Hayashi, M. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970269p · Cited by 69 · cited 4×
“Liposaccharide-based delivery systems were designed to improve bioactive peptides [76, 98] and were shown to enhance their bioavailability [77, 98, 103, 104].”
BackgroundInfluentialTorin Huzil, J., Sivaloganathan, S., Kohandel, M., & Foldvari, M. (2011) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.147 · Cited by 69 · cited 1×
“The modification of lipophilicity, addition of solvents and a number of physical methods, (ultrasound, iontophoresis and electroporation), have all increased peptide permeability [82].”
MethodTugyi, R., Mezö, G., Fellinger, E., Andreu, D., & Hudecz, F. (2005) · Journal of Peptide Science · doi:10.1002/psc.669 · Cited by 68 · cited 2×
“Cyclic variants including a disulfide bridge and peptide bond were demonstrated to increase resistance to degradation with 29% and 73% of the peptide remaining, respectively [135].”
BackgroundBroadening the approaches to developing more effective vaccines
Babiuk, L. A. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00419-8 · Cited by 67 · cited 1×
“Subunit peptide vaccines only include the minimal antigenic components required for vaccine efficacy [44].”
BackgroundStrategies for non-invasive delivery of biologics
Chung, S. W., Hil-lal, T. A., & Byun, Y. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.693499 · Cited by 67 · cited 1×
“Absorption enhancers have been used with some success for overcoming these barriers, however many have been shown to damage the sensitive nasal mucosa [86].”
BackgroundDegarelix: A gonadotropin-releasing hormone antagonist for the management of prostate cancer
Steinberg, M. B. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.009 · Cited by 67 · cited 8×
“A large number of potential peptide therapeutics have not been FDA approved because of their poor physico-chemical characteristics, thus further exploration of techniques aimed at improving the properties of potential peptide therapeutics is critical to the success of this field.”
InfluentialLehmann, A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1187 · Cited by 66
Current Prodrug Design for Drug Discovery
Hsieh, P., Hung, C., & Fang, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788682523 · Cited by 64 · cited 1×
“This use of a pro-drug strategy enhanced the pharmacological characteristics of the peptide without decreasing its activity or selectivity [95].”
BackgroundRizzolo, F., Sabatino, G., Chelli, M., Rovero, P., & Papini, A. M. (2007) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-006-9066-8 · Cited by 62 · cited 1×
“SPPS was used to make Gramicidin A (peptide antibiotic) and CSF114(Glc) (a glycopeptide immunological probe) with a good yield and high purity [12].”
MethodMucosal Immunisation: Adjuvants and Delivery Systems
Moyle, P. M., McGeary, R. P., Blanchfield, J. T., & Tóth, I. (2004) · Current Drug Delivery · doi:10.2174/1567201043334588 · Cited by 60 · cited 1×
“Unlike some other formulations, peptide-based subunit vaccines exist as one entity inclusive of all components essential for a successful vaccine, incorporating adjuvant, carrier and antigen [46, 47].”
BackgroundIndustrial Applications of Solid-Phase Peptide Synthesis – A Status Report
Verlander, M. S. (2007) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-006-9075-7 · Cited by 59 · cited 8×
“A large number of potential peptide therapeutics have not been FDA approved because of their poor physico-chemical characteristics, thus further exploration of techniques aimed at improving the properties of potential peptide therapeutics is critical to the success of this field.”
InfluentialSando, L., Henriques, S. T., Foley, F., Simonsen, S. M., Daly, N. L., Hall, K. N., Gustafson, K. R., Aguilar, M., & Craik, D. J. (2011) · ChemBioChem · doi:10.1002/cbic.201100450 · Cited by 56 · cited 1×
“The cyclotide activity was independent of a protein receptor and dependent on peptide oligomerization at the membrane surface [143].”
BackgroundCui, Z., Han, S., & Huang, L. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000029292.66792.4f · Cited by 55 · cited 1×
“The conjugation of carbohydrate moieties to ovalbumin (OVA, derived from egg white protein) enhanced antigen presentation [64], while coating liposome-protamine-DNA nanoparticles with mannan enhanced the immunogenicity of a human papilloma virus-derived peptide epitope [65].”
BackgroundNasal and rectal delivery of insulin with chitosan and N-trimethyl chitosan chloride
Plessis, D., Kotzé, A. F., & Junginger, H. E. (2010) · Drug Delivery · doi:10.3109/10717541003762888 · Cited by 55 · cited 1×
“Intranasal delivery of insulin has been thoroughly investigated and a number of nanoparticle systems have recently shown promise in animal models [87, 88].”
BackgroundFöldvári, M., Baca‐Estrada, M. E., He, Z., Hu, J., ATTAH‐POKU, S. K., & King, M. (1999) · PubMed · Cited by 55
Won, J., & Barron, A. E. (2002) · Macromolecules · doi:10.1021/ma020892i · Cited by 55 · cited 1×
“The assembly of a polymeric, tandemrepeat cDNA sequence coding for peptide units separated by stable or cleavable linkers has been used for expressing smaller peptides [30].”
MethodChandna, P., Khandare, J. J., Ber, E., Rodrı́guez-Rodrı́guez, L., & Minko, T. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0235-2 · Cited by 53 · cited 1×
“This multifunctional polymer conferred enhanced antitumor activity over the camptothecin-PEG conjugate alone [131].”
BackgroundBerezowska, I., Chung, N. N., Lemieux, C., Wilkes, B. C., & Schiller, P. W. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061294n · Cited by 53 · cited 1×
“Enkephalin [137], oxytocin [138], -conotoxin IMI [139] and lanreotide [140] were subjected to RCM modifications.”
MethodWhy is Exubera being withdrawn?
Bailey, C. J., & Barnett, A. H. (2007) · BMJ · doi:10.1136/bmj.39409.507662.94 · Cited by 53
Tóth, I., Flinn, N. S., Hillery, A. M., Gibbons, W. A., & Artursson, P. (1994) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)90108-2 · Cited by 52 · cited 3×
“This specific cleavage mechanism was also observed in plasma and kidney preparations [92, 96].”
BackgroundOlive, C., Schulze, K., Sun, H. K., Ebensen, T., Horváth, A., Tóth, I., & Guzmán, C. A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.11.031 · Cited by 51 · cited 1×
“trachomatis) [56], human papillomavirus [57], and Streptococcus pyogenes [58-62].”
Backgroundde Bont, D. B. A., Moree, W. J., & Liskamp, R. M. J. (1996) · Bioorganic & Medicinal Chemistry · doi:10.1016/0968-0896(96)00061-2 · Cited by 50 · cited 1×
“Most peptidomimetics were synthesized using altered SPPS protocols [117-119].”
MethodSpecific Renal Delivery of Sugar-Modified Low-Molecular-Weight Peptides
Suzuki, K., Susaki, H., Okuno, S., Yamada, H., Watanabe, H. K., & Sugiyama, Y. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38034-6 · Cited by 46 · cited 1×
“The carbohydrate-modified arg-vasopressin peptide bound selectively to microsomal fractions of the liver and kidney [106].”
BackgroundModification of Antimicrobial Peptide with Low Molar Mass Poly(ethylene glycol)
Zhang, G., Han, B., Lin, X., Wu, X., & Yan, H. (2008) · The Journal of Biochemistry · doi:10.1093/jb/mvn134 · Cited by 46 · cited 8×
“The use of polyethylene glycol (PEG)-based resins, particularly ChemMatrix® (CM), showed benefits over traditional polystyrene-based resins [20, 21].”
BackgroundInfluentialIn Vivo Cleavability of a Disulfide-Based Chimeric Opioid Peptide in Rat Brain
Bickel, U., Kang, Y., & Pardridge, W. M. (1995) · Bioconjugate Chemistry · doi:10.1021/bc00032a009 · Cited by 46 · cited 5×
“For example, desmorphin coupled to the OX26 carrier or -endorphin coupled to cationized albumin for delivery across the BBB [129, 130].”
BackgroundInfluentialMoyle, P. M., Olive, C., Ho, M.-F., Pandey, M., Dyer, J., Suhrbier, A., Fujita, Y., & Toth, I. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070287b · Cited by 45 · cited 2×
“trachomatis) [56], human papillomavirus [57], and Streptococcus pyogenes [58-62].”
BackgroundMAKING PEPTIDES AT LARGE SCALE
Thayer, A. M. (2011) · Chemical & Engineering News · doi:10.1021/cen-v089n022.p021 · Cited by 45
Moyle, P. M., Olive, C., Ho, M.-F., Good, M. F., & Toth, I. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060475m · Cited by 43 · cited 1×
“trachomatis) [56], human papillomavirus [57], and Streptococcus pyogenes [58-62].”
BackgroundFragment Condensation of C‐Terminal Pseudoproline Peptides without Racemization on the Solid Phase
Heinlein, C., Silva, D. V., Tröster, A., Schmidt, J., Gross, A., & Unverzagt, C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101270 · Cited by 43 · cited 2×
“In another example of complicated semi-synthesis, the aforementioned Pro RNase1-39 glycopeptide fragment condensation product was coupled to a recombinantly-expressed RNase40-124 peptide fragment using native chemical ligation, producing the full protein [19].”
MethodHojo, K., Maeda, M., & Kawasaki, K. (2004) · Tetrahedron · doi:10.1016/j.tet.2003.12.036 · Cited by 42 · cited 1×
“developed a new, water soluble N-protecting group, 2-[phenyl (methyl)sulfonio]ethoxycarbonyl tetrafluoroborate, which was used to successfully synthesize Leu- and Met-enkephalin peptides in aqueous solution on a TentaGel resin [16].”
MethodTóth, I., Malkinson, J. P., Flinn, N. S., Drouillat, B., Horváth, A., Érchegyi, J., Idei, M., VENETIANER, A., Artursson, P., Lazorova, L., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9910167 · Cited by 41 · cited 1×
“The liposaccharide-modified somatostatin increased the permeability of the parent peptide when tested in vitro across a Caco-2 cell monolayer [105] without eliminating the activity of the lead compound.”
BackgroundUchiyama, T., Kotani, A., Tatsumi, H., Kishida, T., Okamoto, A., Okada, N., Murakami, M., Fujita, T., Fujiwara, Y., Kiso, Y., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007644706286 · Cited by 40 · cited 1×
“In studies using a more stable enkephalin analogue, [D-Ala(2), D-Leu(5)]-enkephalin, it was observed that an increased lipid moiety chain length enhanced its permeability as long as the solubility was not affected [100].”
BackgroundZotti, M. D., Biondi, B., Peggion, C., Park, Y., Hahm, K., Formaggio, F., & Toniolo, C. (2011) · Journal of Peptide Science · doi:10.1002/psc.1364 · Cited by 40 · cited 1×
“The antimicrobial peptide heptaibin primarily consisted of unnatural amino acids and was intact after 12 h treatment with proteolytic enzyme pronase E in Tris buffer [108].”
MethodKellam, B., Drouillat, B., Dékány, G., Starr, M. S., & Tóth, I. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00328-1 · Cited by 40
Peptidomimetics: modifying peptides in the pursuit of better vaccines
Croft, N. P., & Purcell, A. W. (2011) · Expert Review of Vaccines · doi:10.1586/erv.10.161 · Cited by 39 · cited 1×
“The use of peptidomimetics for designing antigens is comprehensively reviewed by Croft and Purcell [48].”
MethodOlive, C., Ho, M., Dyer, J., Lincoln, D., Barozzi, N., Toth, I., & Good, M. F. (2006) · The Journal of Infectious Diseases · doi:10.1086/504266 · Cited by 38 · cited 1×
“Of particular interest, the LCP constructs exhibited significant immunogenic effects without the need for any additional adjuvant [54, 55].”
BackgroundRecent Advances in Microparticle and Nanoparticle Delivery Vehicles for Mucosal Vaccination
McNeela, E. A., & Lavelle, E. C. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_140 · Cited by 37 · cited 1×
“Promisingly, nanoparticle vaccines were shown to provide some degree of protective immunity after mucosal vaccination [69].”
BackgroundA novel synthetic adjuvant enhances dendritic cell function
Phillipps, K. S. M., Wykes, M. N., Liu, X. Q., Brown, M., Blanchfield, J., & Toth, I. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.03038.x · Cited by 34 · cited 1×
“The lipidic tail of the LCP system elicited Toll-like receptor activity, which was observed in vitro by its action on the receptor-transfected human embryonic kidney cells [53].”
BackgroundTargeted delivery of a proapoptotic peptide to tumorsin vivo
Dufort, S., Sancey, L., Hurbin, A., Foillard, S., Boturyn, D., Dumy, P., & Coll, J. (2010) · Journal of drug targeting · doi:10.3109/1061186x.2010.542245 · Cited by 33 · cited 1×
“An arginylglycylaspartic acid peptide recognizing v 3 integrin, which is overexpressed in tumour cells and vasculature, coupled to a proapoptotic peptide killed tumor cells with lower nonspecific cytoxicity than expected from cationic proapoptotic peptides [133].”
BackgroundAbdel‐Aal, A. M., Zaman, M., Fujita, Y., Batzloff, M. R., Good, M. F., & Tóth, I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1007787 · Cited by 32 · cited 1×
“trachomatis) [56], human papillomavirus [57], and Streptococcus pyogenes [58-62].”
BackgroundElgersma, R. C., Rutters-Meijneke, T., de Jong, R., Brouwer, A. J., Posthuma, G., Rijkers, D. T. S., & Liskamp, R. M. J. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b606875h · Cited by 31 · cited 1×
“However, the properties of peptoids have conferred increased flexiblility-thus decreasing affinity-and sulfonamides have been shown to break -helical and -strand secondary structures [122].”
BackgroundSimerská, P., Abdel‐Aal, A. M., Fujita, Y., Moyle, P. M., McGeary, R. P., Batzloff, M. R., Olive, C., Good, M. F., & Tóth, I. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701410p · Cited by 31 · cited 2×
“trachomatis) [56], human papillomavirus [57], and Streptococcus pyogenes [58-62].”
BackgroundThe Fungal Production of Cyclosporinea
Agathos, S. N., Madhosingh, C., MARSHALL, J. W., & Lee, J. D. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb23863.x · Cited by 31 · cited 1×
“Fermentation was used for production of short peptides, such as cyclosporine [25].”
MethodBessler, W. G., Baier, W., Esche, U. V. D., Hoffmann, P., Heinevetter, L., Wiesmüller, K. H., & Jung, G. (1997) · PubMed · Cited by 30
Fast conventional Fmoc solid‐phase peptide synthesis: a comparative study of different activators
Chantell, C. A., Onaiyekan, M. A., & Menakuru, M. (2011) · Journal of Peptide Science · doi:10.1002/psc.1419 · Cited by 29 · cited 1×
“piperidine) [8].”
Fredholt, K., Adrian, C., Just, L., Larsen, D. H., Weng, S., Moss, B., & Friis, G. J. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00196-0 · Cited by 29
Novel Liposaccharide Conjugates for Drug and Peptide Delivery
Drouillat, B., Hillery, A. M., Dékány, G., Falconer, R. A., Wright, K., & Tóth, I. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js9702123 · Cited by 28 · cited 1×
“Liposaccharide-based delivery systems were designed to improve bioactive peptides [76, 98] and were shown to enhance their bioavailability [77, 98, 103, 104].”
BackgroundA Novel Trp-rich Model Antimicrobial Peptoid with Increased Protease Stability
Bang, J. K., Nan, Y. H., Lee, E.-K., & Shin, S.-Y. (2010) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2010.31.9.2509 · Cited by 26 · cited 1×
“The L-peptide, however, lost all activity after the enzymatic treatment [116].”
BackgroundEfficient Enzymatic Glycosylation of Peptides and Oligosaccharides from GalNAc and UTP
Bourgeaux, V., Cadène, M., Piller, F., & Piller, V. (2006) · ChemBioChem · doi:10.1002/cbic.200600369 · Cited by 23 · cited 1×
“glycosylation [39], amidation [40]).”
Koda, Y., Liang, M., Blanchfield, J. T., & Tóth, I. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.12.036 · Cited by 23 · cited 2×
“Liposaccharide-based delivery systems were designed to improve bioactive peptides [76, 98] and were shown to enhance their bioavailability [77, 98, 103, 104].”
BackgroundLipid core peptide technology and group A streptococcal vaccine delivery
Olive, C., Batzloff, M. R., & Tóth, I. (2004) · Expert Review of Vaccines · doi:10.1586/14760584.3.1.43 · Cited by 23 · cited 1×
“Of particular interest, the LCP constructs exhibited significant immunogenic effects without the need for any additional adjuvant [54, 55].”
BackgroundHojo, K., Ichikawa, H., Onishi, M., Fukumori, Y., & Kawasaki, K. (2011) · Journal of Peptide Science · doi:10.1002/psc.1367 · Cited by 23 · cited 1×
“These nanodispersed Boc-amino acids coupled with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride and N-methylmorpholine produced the Leuenkephalin pentapeptide in 89% yield [17].”
Opiate receptor binding affinities of some D-amino acid substituted β-casomorphin analogs
Liebmann, C., Szűcs, M., Neubert, K., Hartrodt, B., Arold, H., & Barth, A. (1986) · Peptides · doi:10.1016/0196-9781(86)90212-3 · Cited by 22 · cited 1×
“D-Amino acid substitutions in -casomorphin were shown to enhance -opioid receptor binding and analgesia [111].”
BackgroundWhelan, A. N., Elaridi, J., Mulder, R. J., Robinson, A. J., & Jackson, W. R. (2005) · Canadian Journal of Chemistry · doi:10.1139/v05-100 · Cited by 22 · cited 1×
“Enkephalin [137], oxytocin [138], -conotoxin IMI [139] and lanreotide [140] were subjected to RCM modifications.”
MethodBundgaard, H. (1981) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(81)90096-x · Cited by 21
Chemical Synthesis of 19F-labeled HIV-1 Protease using Fmoc-Chemistry and ChemMatrix Resin
Frutos, S., Tulla‐Puche, J., Alberício, F., & Giralt, E. (2007) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-006-9070-z · Cited by 21 · cited 1×
“The use of polyethylene glycol (PEG)-based resins, particularly ChemMatrix® (CM), showed benefits over traditional polystyrene-based resins [20, 21].”
MethodOral absorption of lipidic amino acid conjugates
Tóth, I., Hillery, A. M., Wood, I. P., Magnusson, C., & Artursson, P. (1994) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(94)90059-0 · Cited by 21 · cited 1×
“Lipid moieties coupled to peptides conferred the characteristics essential for intestinal delivery [99].”
BackgroundSynthesis and in vivo studies of carbohydrate‐based vaccines against group A Streptococcus
Simerská, P., Abdel‐Aal, A. M., Fujita, Y., Batzloff, M. R., Good, M. F., & Tóth, I. (2008) · Biopolymers · doi:10.1002/bip.20992 · Cited by 20 · cited 1×
“trachomatis) [56], human papillomavirus [57], and Streptococcus pyogenes [58-62].”
BackgroundWong, A. K., Ross, B. P., Chan, Y., Artursson, P., Lazorova, L., Jones, A., & Tóth, I. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00078-7 · Cited by 19 · cited 1×
“Glycosylation of Leuenkephalin at the N- or C-termini enhanced transport profiles in a number of cases [102, 146, 147].”
BackgroundDelivering Needle-Free Insulin Using AERx ® iDMS (Insulin Diabetes Management System) Technology
Wollmer, P., Pieber, T. R., Gall, M.-A., & Brunton, S. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0206 · Cited by 18 · cited 1×
“However, a number of commercial liposome-based technologies have evidenced the viability of peptide drugs for transdermal and pulmonary delivery [79, 80].”
BackgroundBlanchfield, J. T., Lew, R. A., Smith, A. I., & Tóth, I. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.069 · Cited by 17 · cited 1×
“This specific cleavage mechanism was also observed in plasma and kidney preparations [92, 96].”
BackgroundWu, S. Y., Campbell, C., Koda, Y., Blanchfield, J. T., & Tóth, I. (2006) · Medicinal Chemistry · doi:10.2174/157340606776056205 · Cited by 14 · cited 1×
“Glycosylation of Leuenkephalin at the N- or C-termini enhanced transport profiles in a number of cases [102, 146, 147].”
BackgroundEnhancement of the inhibitory effect of an IL‐15 antagonist peptide by alanine scanning
Savio, A. S., Acosta, O. R., Pérez, H. G., Rodríguez‐Álvarez, Y., Chico, A., Pérez, H. G., Ojeda, M. O., Arrieta, C. A., Estévez, M., & Nieto, G. G. (2011) · Journal of Peptide Science · doi:10.1002/psc.1411 · Cited by 13 · cited 1×
“A simple amino acid substitution in the IL-1536-45 peptide led to a change in the half maximal inhibitory concentration from 130 M to 24 M [152].”
BackgroundOlivé, C., Moyle, P. M., & Tóth, I. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707782794069 · Cited by 12 · cited 1×
“Intranasal administration was also shown to be successful with this system [63].”
BackgroundA Method for the High-Level Expression of a Parathyroid Hormone Analog in Escherichia coli
Oldenburg, K. R., Dorfani, A. L., & Selick, H. E. (1994) · Protein Expression and Purification · doi:10.1006/prep.1994.1042 · Cited by 11 · cited 1×
“coli) [26].”
Kawakami, T., Kamo, M., Takamoto, K., Miyazaki, K., Chow, L., Ueno, Y., & Tsugita, A. (1997) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021572 · Cited by 11 · cited 1×
“Acid-labile peptide bonds, such as that of an aspartyl-proline bond [71], contribute to a poor oral bioavailability.”
BackgroundKassem, T., Sabatino, D., Jia, X., Zhu, X. X., & Lubell, W. D. (2009) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-009-9177-0 · Cited by 10 · cited 1×
“suggested that a newly developed resin incorporating PEG polymerized onto a poly(vinyl alcohol) core may be even more valuable, economically and environmentally, after demonstrating its promise against other resins in synthesis of a section of acyl carrier protein [23].”
BackgroundCyclic and linear oligocarbamate ligands for human thrombin
Cho, C. Y., Liu, C. W., Wemmer, D. E., & Schultz, P. G. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00028-0 · Cited by 10 · cited 1×
“Most peptidomimetics were synthesized using altered SPPS protocols [117-119].”
MethodWessling, S. T., Ross, B. P., Koda, Y., Blanchfield, J. T., & Tóth, I. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.04.042 · Cited by 8 · cited 1×
“Liposaccharide-based delivery systems were designed to improve bioactive peptides [76, 98] and were shown to enhance their bioavailability [77, 98, 103, 104].”
BackgroundScope and limitation of side‐chain assisted ligation
Spasser, L., Kumar, K. S. A., & Brik, A. (2011) · Journal of Peptide Science · doi:10.1002/psc.1336 · Cited by 7 · cited 1×
“A modified method used auxillary thiols in place of the cysteine residues, which were removed at the site of ligation and allowed the formation of a noncysteine linkage [14, 15].”
MethodStructures of peptide agonists for human protease activated receptor 2
Stoermer, M. J., Flanagan, B. M., Beyer, R. L., Madala, P. K., & Fairlie, D. P. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.029 · Cited by 2 · cited 1×
“These short peptide sequences were of therapeutic interest because they activated the receptor on immunoinflammatory and cancer cells, amongst others [149].”
Background
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
“lactamization, lactonization, and sulfide-based bridges (4).”
BackgroundMultifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action
Akbarian, M., Khani, A., Eghbalpour, S., & Uversky, V. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031445 · Cited by 612
“glycoprotein CSF114, which are used for infectious diseases and the clinical diagnosis of multiple sclerosis, respectively [42].”
Background
Metadata
- Authors
- Goodwin, D., Simerska, P., & Toth, I.
- Affiliations
- The University of Queensland (AU)
- ORCID
- Goodwin, D.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-01
- Volume
- 19
- Issue
- 26
- Pages
- 4451-4461
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2162532167
- Cited by
- 176
- References
- 142
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 15 · 2021: 20 · 2020: 14 · 2019: 14 · 2018: 19 · 2017: 17 · 2016: 16 · 2015: 9 · 2014: 14 · 2013: 8
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- U.S. Food and Drug Administration
- Australian Research Council
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- peptide therapeutics, peptide synthesis, peptide stability, bioavailability, drug delivery, peptide vaccine, adjuvants, immunogenicity, peptide modification, clinical trials
- MeSH terms
- Amino Acid Sequence, Animals, Humans, Peptides, Vaccines, Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.